Perioperative Anticoagulation Bridging: CHADS2, Mechanical Valves, and DOACs

Perioperative anticoagulation bridging refers to the temporary substitution of chronic oral anticoagulation with short-acting parenteral anticoagulants during the perioperative period to minimize both bleeding and thromboembolic risks.

[KEY_CONCEPT] The fundamental challenge lies in balancing thrombotic risk from anticoagulation interruption against bleeding risk from continuing anticoagulation during surgery.

Pathophysiology of Perioperative Thrombosis

Surgical procedures activate multiple prothrombotic mechanisms:

• Tissue factor release from surgical trauma
• Platelet activation and aggregation
• Inflammation-mediated coagulation cascade activation
• Immobilization leading to venous stasis
• Dehydration and increased blood viscosity

Anticoagulation Pharmacokinetics

[CLINICAL_PEARL] The "bridge" typically involves stopping long-acting oral anticoagulants 5 days preoperatively and starting therapeutic LMWH or UFH, then resuming oral agents postoperatively once bleeding risk decreases.

Thrombotic Risk Assessment

CHADS2 Score for Atrial Fibrillation

Components (1 point each, except stroke = 2 points):

• Congestive heart failure
• Hypertension
• Age ≥75 years
• Diabetes mellitus
• Stroke/TIA history (2 points)

Risk Stratification:

• Low risk (CHADS2 0-2): Annual stroke risk <4%
• Moderate risk (CHADS2 3-4): Annual stroke risk 4-6%
• High risk (CHADS2 5-6): Annual stroke risk >6%

[HIGH_YIELD] CHA2DS2-VASc is preferred over CHADS2 for more precise risk stratification, adding vascular disease, age 65-74, and female sex as additional factors.

Mechanical Valve Risk Assessment

High-risk features:

• Recent thromboembolism (<6 months)
• Multiple mechanical valves
• Mitral valve replacement
• Atrial fibrillation
• LV dysfunction (EF <35%)

Bleeding Risk Assessment

Revised Cardiac Risk Index (RCRI)

Risk Factors (1 point each):

1. High-risk surgery (intraperitoneal, intrathoracic, suprainguinal vascular)
2. Ischemic heart disease
3. Congestive heart failure
4. Cerebrovascular disease
5. Diabetes requiring insulin
6. Creatinine >2.0 mg/dL

[CLINICAL_PEARL] High bleeding risk procedures include neurosurgery, cardiac surgery, major vascular surgery, and urologic procedures with bleeding risk >2%.

Preoperative Evaluation Algorithm

Patient on chronic anticoagulation scheduled for surgery | v Assess thrombotic risk | +---------------+---------------+ | | LOW RISK HIGH RISK

• CHADS2 0-2 - CHADS2 ≥3
• Aortic mechanical valve - Mitral mechanical valve
• No recent VTE - Recent VTE (<3 months) | | v v Assess bleeding risk Assess bleeding risk | | +---------------+---------------+ | | LOW BLEEDING RISK HIGH BLEEDING RISK
• Minor procedures - Major surgery
• Bleeding risk <2% - Neuraxial anesthesia | | v v Continue anticoagulation Consider bridging

Laboratory Assessment

Baseline Studies Required

• Complete blood count with platelet count
• Comprehensive metabolic panel (creatinine clearance)
• Coagulation studies: PT/INR, aPTT
• Liver function tests

Drug-Specific Monitoring

[HIGH_YIELD] DOAC levels can be assessed using drug-specific anti-Xa assays (rivaroxaban, apixaban) or dilute thrombin time (dabigatran), though routine monitoring is not required.

Risk Assessment Tools

HAS-BLED Score for Bleeding Risk

• Hypertension (>160 mmHg)
• Abnormal liver/kidney function
• Stroke history
• Bleeding tendency
• Labile INRs
• Elderly (>65 years)
• Drugs/alcohol

[KEY_CONCEPT] Scores ≥3 indicate high bleeding risk requiring careful consideration of anticoagulation continuation.

Bridging Decision Framework

Evidence-Based Approach

[HIGH_YIELD] The BRIDGE trial demonstrated that bridging with LMWH in AF patients with CHADS2 ≤4 increased bleeding risk without reducing thromboembolism, challenging routine bridging practices.

Management by Indication

Atrial Fibrillation

High Risk (Consider Bridging):

• CHADS2 ≥5 or CHA2DS2-VASc ≥6
• Recent stroke/TIA (<3 months)
• Rheumatic heart disease

Low-Moderate Risk (No Bridging):

• CHADS2 ≤4 and CHA2DS2-VASc ≤5
• No recent thromboembolic events

Mechanical Heart Valves

Always Bridge:

• Mitral valve replacement
• Recent thromboembolism (<6 months)
• Multiple mechanical valves

Consider Bridging:

• Aortic valve replacement with additional risk factors
• Tilting disc or ball-cage valves

DOAC Management Protocol

Perioperative DOAC Timing

DOAC Perioperative Management | v Assess bleeding risk | +---------+---------+ | | LOW RISK HIGH RISK (minor surgery) (major surgery) | | v v Stop 24h before Stop 48-72h before Resume 6-8h post Resume 24-72h post

[CLINICAL_PEARL] DOACs generally do not require bridging due to their rapid onset/offset, except in very high-risk patients where bridging may be considered on a case-by-case basis.

Bridging Protocols

Standard LMWH Bridging

• Enoxaparin 1 mg/kg SC BID (therapeutic dosing)
• Last dose 12-24 hours before surgery
• Resume 12-24 hours post-surgery (if hemostasis adequate)

UFH Bridging (Inpatient)

• Initial bolus: 80 units/kg IV
• Infusion: 18 units/kg/hr, adjust to aPTT 1.5-2.5× control
• Stop 4-6 hours before surgery
• Resume 12-24 hours post-surgery

Perioperative Complications

Thrombotic Complications

Arterial Thromboembolism:

• Stroke/TIA: Most feared complication in AF and mechanical valves
• Systemic embolism: Peripheral arterial occlusion
• Myocardial infarction: Especially in CAD patients

Venous Thromboembolism:

• Pulmonary embolism: High mortality if untreated
• Deep vein thrombosis: May progress to PE

[HIGH_YIELD] Thrombotic events typically occur 1-7 days postoperatively when anticoagulation is subtherapeutic.

Bleeding Complications

Major Bleeding Criteria:

• Hemoglobin drop ≥2 g/dL
• Transfusion requirement ≥2 units PRBC
• Critical organ bleeding (intracranial, retroperitoneal)
• Bleeding requiring reoperation

Risk Factors for Perioperative Bleeding:

• Age >75 years
• Renal dysfunction (CrCl <50 mL/min)
• Concomitant antiplatelet therapy
• History of bleeding
• Bridging anticoagulation

Monitoring Protocols

Laboratory Monitoring

Reversal Strategies

Emergency Reversal Agents:

[CLINICAL_PEARL] Four-factor PCC (Kcentra) is preferred over FFP for warfarin reversal due to faster onset and smaller volume.

Landmark Trial Evidence

BRIDGE Trial (NEJM 2015)

• Population: 1,884 AF patients with CHADS2 ≤4
• Intervention: Bridging with dalteparin vs. placebo
• Results: No difference in arterial thromboembolism (0.4% vs 0.3%)
• Bleeding: Significantly increased major bleeding (3.2% vs 1.3%)

[KEY_CONCEPT] This trial fundamentally changed bridging practice, demonstrating that routine bridging in moderate-risk AF patients increases bleeding without preventing thromboembolism.

POISE-2 Trial

• Demonstrated: Aspirin in perioperative period increases bleeding without cardiovascular benefit
• Implication: Supports careful consideration of all antithrombotic therapies perioperatively

Current Guidelines Summary

2017 AHA/ACC/HRS Guideline Recommendations

Class I (Should Do):

• Bridge patients with mechanical mitral valves
• Bridge patients with recent stroke/TIA (<3 months)

Class IIb (May Consider):

• Bridge AF patients with CHA2DS2-VASc ≥6
• Bridge patients with aortic mechanical valves plus risk factors

Class III (Should Not Do):

• Routine bridging in AF patients with CHA2DS2-VASc ≤4

Risk-Benefit Analysis

Factors Favoring Bridging

• Very high thrombotic risk (annual risk >10%)
• Mechanical mitral valve
• Recent thromboembolism (<3 months)
• Multiple risk factors for thrombosis

Factors Against Bridging

• High bleeding risk surgery
• History of major bleeding
• Poor anticoagulation control
• Advanced age with frailty

Long-Term Outcomes

Prognosis by Risk Group

[CLINICAL_PEARL] Shared decision-making with patients is essential, as individual values regarding stroke vs. bleeding risk vary significantly.

Quality Metrics

• Appropriate bridging rate: <30% of AF patients
• Major bleeding rate: <3% with selective bridging
• Thromboembolism rate: <1% in low-moderate risk patients

[HIGH_YIELD] Modern perioperative anticoagulation management emphasizes risk stratification over routine bridging, with most AF patients and DOAC users not requiring bridging therapy.